-
Professors Bing Chen and Lijuan Chen’s Team: FUMANBA-2 Study Opens New Horizons for Treating High-Risk Newly Diagnosed Multiple Myeloma
The 29th Annual Congress of the European Hematology Association (EHA) took place from June 13 to June 16, 2024, in Madrid, Spain. On the afternoon of June 15, local time, Professor Bing Chen from Nanjing Drum Tower Hospital affiliated with Nanjing University Medical School presented the latest data from the FUMANBA-2 study in an oral…
-
2024 CSCO YOUNG丨Aspiring Towards the Future : Professor Zefei Jiang Discusses the CSCO Youth Expert Committee and the Growth Path for Young Doctors
With the rapid development of the medical field, the growth and demeanor of young doctors, as future pillars of healthcare, are highly anticipated. At the mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) in 2024, Professor Zefei Jiang from the Medical School of Chinese People’s Liberation Army…
-
ASCO 2024 | Biomarkers and Efficacy Analysis of Immunotherapy Combinations for Metastatic Prostate Cancer
The efficacy of endocrine therapy in advanced prostate cancer patients is poor, with most ultimately progressing to castration-resistant prostate cancer (CRPC). Although previous single-agent immunotherapies have shown limited success in prostate cancer, recent studies indicate that combination immunotherapies exhibit higher antitumor activity in patients with metastatic CRPC (mCRPC). At the recent ASCO Annual Meeting, a…
-
Can COVID-19 Vaccination Help Long COVID Symptoms?
A recent study in The Journal of Infection suggests that SARS-CoV-2 vaccination may accelerate symptom resolution in individuals with ongoing symptomatic COVID-19 (OSC) and post-COVID syndrome (PCS). Using data from the ZOE COVID Symptom Study app, researchers found that vaccinated individuals experienced greater improvement in symptoms like fatigue and brain fog compared to unvaccinated individuals.
-
New Breakthrough in SARS-CoV-2 Immunotherapy
A recent study published in Emerging Microbes & Infections introduces C10, a pan-SARS-CoV-2 monoclonal antibody (mAb) that offers a novel approach to combating COVID-19. Unlike traditional neutralizing antibodies, C10 targets infected lung epithelial cells and mediates their elimination via NK cell-driven antibody-dependent cellular cytotoxicity (ADCC).
-
ASCO GU 2025 | Dr. Kan Gong & Dr. Eric Jonasch Continue Their Discussion on Belzutifan and Advanced Renal Cancer (Part II)
In the second part of their discussion at ASCO GU 2025, Dr. Kan Gong (Peking University First Hospital) and Dr. Eric Jonasch (MD Anderson Cancer Center) examined the evolving role…
-
ASCO GU 2025 | Dr. Kan Gong & Dr. Eric Jonasch on Belzutifan and the LightSpark 015 Study
At ASCO GU 2025, Dr. Kan Gong (Peking University First Hospital) and Dr. Eric Jonasch (MD Anderson Cancer Center) discussed VHL-associated renal cell carcinoma (RCC) and the latest Belzutifan data.…
-
China-Europe Collaboration Brings New Hope for Cholangiocarcinoma Treatment – An Exclusive Interview with Dr. Chiara Braconi
From February 20 to 22, 2025, the European Association for the Study of the Liver (EASL) Liver Cancer Summit was held in Paris, France. The first day of the conference was dedicated to Cholangiocarcinoma (CCA). Dr. Chiara Braconi, a leading expert in cholangiocarcinoma treatment from the University of Glasgow, UK, delivered a keynote lecture and…
Connecting Medical Expertise through Media